Short Interest in Shattuck Labs, Inc. (NASDAQ:STTK) Grows By 196.4%

Shattuck Labs, Inc. (NASDAQ:STTK) was the recipient of a significant increase in short interest during the month of August. As of August 15th, there was short interest totaling 1,280,000 shares, anincreaseof196.4% from the July 31st total of 431,800 shares. Approximately3.1% of the company’s shares are sold short. Based on an average trading volume of 1,850,000 shares, the short-interest ratio is presently 0.7 days. Based on an average trading volume of 1,850,000 shares, the short-interest ratio is presently 0.7 days. Approximately3.1% of the company’s shares are sold short.

Insider Activity

In related news, Director Mona Ashiya purchased 6,306,127 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The stock was bought at an average cost of $0.87 per share, with a total value of $5,486,330.49. Following the completion of the purchase, the director directly owned 5,255,106 shares in the company, valued at approximately $4,571,942.22. This represents a -600.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Orbimed Advisors Llc purchased 6,306,127 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The stock was bought at an average cost of $0.87 per share, with a total value of $5,486,330.49. Following the completion of the purchase, the director owned 5,255,106 shares of the company’s stock, valued at $4,571,942.22. This represents a -600.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 12.00% of the company’s stock.

Institutional Investors Weigh In On Shattuck Labs

Several institutional investors and hedge funds have recently made changes to their positions in the company. Northern Trust Corp increased its position in shares of Shattuck Labs by 9.2% during the fourth quarter. Northern Trust Corp now owns 353,616 shares of the company’s stock valued at $428,000 after acquiring an additional 29,870 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Shattuck Labs by 265.4% during the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock valued at $41,000 after acquiring an additional 31,355 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new stake in shares of Shattuck Labs during the fourth quarter valued at approximately $45,000. 683 Capital Management LLC increased its position in shares of Shattuck Labs by 4.3% during the second quarter. 683 Capital Management LLC now owns 1,095,000 shares of the company’s stock valued at $867,000 after acquiring an additional 45,000 shares in the last quarter. Finally, Nuveen LLC bought a new stake in shares of Shattuck Labs during the first quarter valued at approximately $50,000. Institutional investors own 58.74% of the company’s stock.

Shattuck Labs Stock Performance

Shares of NASDAQ STTK opened at $1.55 on Friday. Shattuck Labs has a fifty-two week low of $0.69 and a fifty-two week high of $3.95. The company has a 50 day simple moving average of $0.89 and a two-hundred day simple moving average of $1.00. The company has a market capitalization of $74.25 million, a price-to-earnings ratio of -1.28 and a beta of 1.64.

Shattuck Labs (NASDAQ:STTK) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.01. On average, analysts forecast that Shattuck Labs will post -1.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Wall Street Zen raised shares of Shattuck Labs to a “hold” rating in a research note on Friday. Leerink Partners decreased their target price on shares of Shattuck Labs from $4.00 to $2.00 and set an “outperform” rating for the company in a research note on Thursday, August 14th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Shattuck Labs in a research note on Thursday, August 14th. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, Shattuck Labs presently has a consensus rating of “Moderate Buy” and an average target price of $4.00.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.